FLAER iFluor488

Overview

This product is a FLAER-based probe commonly used in flow cytometry to assess the presence of glycosylphosphatidylinositol (GPI) anchors on the surface of mammalian cells. Because many cell-surface proteins are displayed via GPI anchoring, FLAER is widely used to distinguish GPI-positive from GPI-deficient populations in mixed samples, including applications related to paroxysmal nocturnal hemoglobinuria (PNH).

Key elements and design rationale

• Target concept: FLAER (fluorescently labeled aerolysin) is derived from an inactive proaerolysin variant that binds the GPI anchor moiety present on many mammalian cell-surface proteins, enabling detection of GPI anchor expression by flow cytometry.
• Antigen / binding context: The probe recognizes the GPI anchor itself rather than a single GPI-linked protein (such as CD55 or CD59), which can help provide confirmatory information when studying GPI-deficient cell subsets.
• Conjugate / label: iFluor488 conjugation supports direct fluorescence readout in flow cytometry panels, helping streamline multiparameter analysis and enabling channel selection based on the fluorophore used.
• Applications: Listed for FC; commonly used as a probe in flow cytometry workflows to assess GPI anchor expression status.
• Reactivity: Reported reactivity is Mammalian GPI Protein; confirm performance in your specific sample type and panel design.

Researchers typically interpret FLAER staining as a readout of “GPI anchor presence” on the cell surface. As with any membrane-associated marker, signal levels can vary with cell type, activation state, and sample handling, so panel design and appropriate controls are important for robust interpretation.

Biological background

GPI anchors are glycolipids that tether diverse proteins to the outer leaflet of the plasma membrane. GPI-anchored proteins participate in cell–cell interactions, complement regulation, enzymatic processes, and signaling microdomains (often discussed in the context of lipid rafts). The cellular pathway that assembles and remodels GPI anchors involves many enzymes and trafficking steps, and disruption of this pathway can alter the surface display of multiple proteins at once.

Paroxysmal nocturnal hemoglobinuria (PNH) is a clonal hematopoietic stem cell disorder most commonly associated with acquired mutations affecting GPI-anchor biosynthesis (classically involving PIGA). This results in blood cell populations that lack GPI-anchored complement regulators (commonly referenced examples include CD55 and CD59), contributing to complement-mediated hemolysis and a prothrombotic phenotype. Flow cytometry is the standard approach to identify and monitor GPI-deficient clones, and FLAER-based panels are widely used in that context.

Research relevance and current trends

• Higher-resolution clone detection: Multiparameter flow cytometry panels combining FLAER with lineage markers and additional GPI-linked proteins are commonly used to improve discrimination of small GPI-deficient populations and to support longitudinal monitoring.
• Mechanistic studies of GPI anchoring: Interest in the genetics and lipid remodeling steps of GPI-anchor biosynthesis has increased, including studies that perturb specific enzymes to understand how anchor structure affects surface expression and immune recognition.
• Interpretation and standardization: Community guidelines and method comparisons continue to refine gating strategies and control concepts for PNH-related testing, highlighting the importance of robust lineage definition and awareness of marker variability across clinical contexts.

Common research applications

• PNH-related workflows: Distinguish GPI-positive vs GPI-deficient leukocyte subsets (e.g., granulocytes, monocytes, lymphocytes) using FLAER within multiparameter flow cytometry panels.
• GPI-anchor biology: Compare the impact of genetic perturbations, differentiation state, or pharmacologic treatments on the surface display of GPI-anchored proteins in cultured cells.
• Panel development: Use FLAER alongside antibodies to specific GPI-linked proteins (e.g., CD55/CD59) as complementary readouts when interpreting partial loss, lineage differences, or epitope-dependent variability.

The supplied product description emphasizes that FLAER binds GPI-anchored proteins on the cell surface in healthy samples and can fail to bind GPI-deficient cells in PNH, which is the conceptual basis for clone identification by flow cytometry. In practice, researchers often interpret “FLAER-negative” events as candidate GPI-deficient populations, then evaluate consistency across lineages and markers.

Notes for experimental interpretation

• Species and sample context: FLAER is commonly used with mammalian cells; differences in GPI-anchor composition and surface density across cell types can influence signal distributions.
• Marker and lineage considerations: When the goal is to identify rare GPI-deficient subsets, lineage definition (e.g., myeloid vs lymphoid gates) and inclusion of additional markers can help reduce ambiguity in interpretation.
• Control concepts: Consider control samples expected to be GPI-positive, and when studying perturbations, compare to matched untreated or wild-type controls to support interpretation of shifts in FLAER signal.

• TDS (PDF)
• MSDS (PDF)

Can’t Find What You’re Looking For? We can help you source the best match or customize a recombinant protein solution for your study. Options may include species (human/mouse/rat), protein region/domain (full-length vs fragment), tag or label (His/GST/FLAG/biotin/fluorescent), expression system (E. coli/HEK293/insect), purity grade, formulation (buffer, carrier-free, glycerol-free), activity/functional validation (binding or enzymatic assays), endotoxin level (low-endotoxin for cell-based work), mutants/variants (point mutations, isoforms), and bulk or custom packaging. Click Talk to a Scientist to submit a request form, email us at support@biohippo.com, or explore our Research Services for additional support. Our team will be in contact with you shortly.